Cingulate Inc. (CING)
| Market Cap | 67.97M +302.3% |
| Revenue (ttm) | n/a |
| Net Income | -27.91M |
| EPS | -4.24 |
| Shares Out | 13.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 720,558 |
| Open | 4.88 |
| Previous Close | 4.74 |
| Day's Range | 4.65 - 5.30 |
| 52-Week Range | 3.16 - 11.89 |
| Beta | -0.85 |
| Analysts | Strong Buy |
| Price Target | 23.31 (+355.27%) |
| Earnings Date | May 14, 2026 |
About CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CING stock is "Strong Buy." The 12-month stock price target is $23.31, which is an increase of 355.27% from the latest price.
News
Cingulate issues patent by USPTO for CTx-1301
Cingulate (CING) announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301, for the treatment of Attention Deficit Hyperactivity Disorder, or ADHD. The patent, is...
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-...
Roth sees ‘major silver lining’ in Cingulate complete response letter
Roth Capital says a “major silver lining” of Cingulate’s (CING) complete response letter for CTx-1301 is that no safety and clinical deficiencies were raised by the FDA. While management expects…
Cingulate issued complete response letter for CTx-1301 from FDA
Cingulate (CING) announced that the FDA has issued a complete response letter for its new drug application for CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. The resp...
US FDA declines to approve Cingulate's ADHD drug
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is...
Cingulate Proxy statement: Proxy filing
Cingulate filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate Proxy statement: Proxy filing
Cingulate filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate price target lowered to $10 from $14 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $10 from $14 and keeps a Buy rating on the shares, citing Q1 updates for the…
Cingulate Proxy statement: Proxy filing
Cingulate filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to devel...
Cingulate Earnings release: Q1 2026
Cingulate released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cingulate Quarterly report: Q1 2026
Cingulate has published its Q1 2026 quarterly earnings report on May 14, 2026.
Cingulate files to sell 4.21M shares of common stock for holders
17:27 EDT Cingulate (CING) files to sell 4.21M shares of common stock for holders
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on April 14, 2026, providing details about a securities offering with the SEC.
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues t...
Cingulate Slides: Corporate presentation
Cingulate has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on March 23, 2026, providing details about a securities offering with the SEC.
Cingulate price target lowered to $14 from $16 at Roth Capital
Roth Capital lowered the firm’s price target on Cingulate (CING) to $14 from $16 and keeps a Buy rating on the shares. The company’s new drug application for CTx-1301 in…
Cingulate Registration statement: Registration filing
Cingulate filed a registration statement on March 20, 2026, providing details about a securities offering with the SEC.
Cingulate files to sell 3.5M shares of common stock for holders
07:40 EDT Cingulate (CING) files to sell 3.5M shares of common stock for holders
Cingulate announces U.S. patent notice of allowance
On Tuesday, March 17th, 2026, the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering Cingulate’s (CING) lead ADHD candidate, CTx-1301, indicating ...
Cingulate reports Q4 net loss $6.3M vs. $6.2M last year
Cingulate (CING) CEO Shane Schaffer stated, “Cingulate delivered on key inflection points throughout 2025 and this continues into 2026. Cingulate is proud to announce that CTx-1301 has strengthened it...
Cingulate sees cash runway into late 4Q26
As of December 31, 2025, Cingulate (CING) had approximately $11.0 million in cash and cash equivalents, a $1.3 million decrease from December 31, 2024. The Company expects current cash on…